Clinical observation of intermedium-dose cytarabine for consolidation therapy of elderly patients with acute myelogenous leukemia
10.3760/cma.j.issn.1009-9921.2017.05.005
- VernacularTitle:中剂量阿糖胞苷用于老年急性髓系白血病患者巩固强化治疗的临床观察
- Author:
Menghuan CHEN
;
Silin GAN
;
Hui SUN
;
Yanfang LIU
;
Zhongxing JIANG
;
Dingming WAN
;
Xinsheng XIE
;
Jie MA
- Keywords:
Leukemia;
myeloid;
acute;
Aged;
Cytarabine;
Consolidation therapy
- From:
Journal of Leukemia & Lymphoma
2017;26(5):276-279
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of postremission consolidation therapy with intermedium-dose cytarabine (MDAC) in elderly patients with acute myelogenous leukemia (AML). Methods Clinical data of 61 elderly AML patients (except M3) in postremission who achieved complete remission (CR) in two period of remission induction program were retrospectively analyzed. Results There were 26 cases in MDAC group and 35 cases in standard-dose cytarabine (SDAC) group. In MDAC group and SDAC group, the relapse free survival (RFS) time were 42.7 months and 16.0 months respectively (P= 0.002), the overall survival (OS) time were 44.6 months and 18.2 months respectively (P= 0.004), and the cumulative relapse frequencies rates were 26.9 % (7/26) and 54.3 % (19/35) respectively (x 2= 4.567, P= 0.033). However, 3 years OS rate of the two groups were 23.1%(6/26) and 8.6%(3/35) (x 2=2.496, P=0.114) , and there was no significant difference in the incidence of adverse reactions between the two groups (all P > 0.05). Conclusion MDAC could improve RFS and OS for the elderly AML patients in postremission who received CR in the early stage, and the incidence of adverse reactions is similar to that of SDAC.
